投资者

/投资者
投资者 2018-05-30T18:41:16+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

5.61
0.12 (2.09%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :3,033
Date :07-20-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

三月 22nd, 2017|Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017已关闭评论

JERUSALEM, March 22, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, [...]

Oramed Appoints Dr. Ronald Law as Chief Strategy Officer

三月 21st, 2017|Oramed Appoints Dr. Ronald Law as Chief Strategy Officer已关闭评论

JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer. [...]

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

二月 7th, 2017|Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences已关闭评论

JERUSALEM, Feb. 7, 2017  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming [...]

Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

十一月 29th, 2016|Oramed’s ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study已关闭评论

Preparing to submit IND and commence U.S. FDA Phase IIb trial in 2017 JERUSALEM, Nov. 29, 2016  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it [...]